Combining Antiangiogenic Therapy with Immune Checkpoint Inhibitor for Advanced Hepatocellular Carcinoma

Take home messages
1. IMbrave150 confirms the benefits of combining antiangiogenic therapy with immunecheckpoint inhibitors as advanced HCC treatment
2. Bevacizumab+ atezolizumab is the first regimen that beats sorafenib in overall survival benefits for advanced HCC patients
3. Other antiangiogenic therapy + immune checkpoint inhibitor combinations have encouraging phase 1 study results but need to be confirmed in phase 3 studies